natgillin/translations-raw huggingface dataset:
No dose adjustment is recommended in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment, however, PREZISTA should be used with caution in these patients.
Pri bolnikih z blago (razred A po Child- Pughovi lestvici) ali zmerno (razred B po Child- Pughovi lestvici) jetrno okvaro ni potrebno prilagajati odmerka, vseeno pa je potrebna previdnost pri uporabi zdravila PREZISTA pri teh bolnikih.
No pharmacokinetic data are available in patients with severe hepatic impairment.
Farmakokinetični podatki pri bolnikih s hudo jetrno okvaro niso na voljo.
Severe hepatic impairment could result in an increase of darunavir exposure and a worsening of its safety profile.
Zato se lahko pri hudi jetrni okvari izpostavljenost darunavirju poveča in poslabša njegov varnostni profil.
Therefore, PREZISTA should not be used in patients with severe hepatic impairment (Child-Pugh Class C) (see sections 4.3, 4.4 and 5.2).
Zato se zdravila PREZISTA pri bolnikih s hudo jetrno okvaro (razred C po Child- Pughovi lestvici) ne sme uporabljati (glejte poglavja 4. 3, 4. 4 in 5. 2).
No dose adjustment is required in patients with renal impairment (see sections 4.4 and 5.2).
Pri bolnikih z ledvično okvaro prilagajanje odmerka ni potrebno (glejte poglavji 4. 4 in 5. 2).
2 In case a dose of PREZISTA and/ or ritonavir was missed within 6 hours of the time it is usually taken, patients should be instructed to take the prescribed dose of PREZISTA and ritonavir with food as soon as possible.
V primeru, da je bil odmerek zdravila PREZISTA in/ ali ritonavirja izpuščen in je bilo to opaženo do 6 ur od časa, ko je ponavadi zaužit, je treba bolniku svetovati, naj čimprej vzame predpisani odmerek zdravila PREZISTA in ritonavirja s hrano.
If this was noticed later than 6 hours of the time it is usually taken, the missed dose should not be taken and the patient should resume the usual dosing schedule.
Če je bilo to opaženo več kot 6 ur od časa, ko je ponavadi zaužit, izpuščenega odmerka ne sme zaužiti in nadaljuje z naslednjim odmerkom po običajnem režimu odmerjanja.
This guidance is based on the 15 hour half-life of darunavir in the presence of ritonavir and the recommended dosing interval of approximately 12 hours.
To navodilo je osnovano na 15 urnem razpolovnem času darunavirja v prisotnosti ritonavirja in priporočenem režimu odmerjanja na približno 12 ur.
Patients with severe (Child-Pugh Class C) hepatic impairment.
Bolniki s hudo jetrno okvaro (razred C po Child- Pughovi lestvici).
Combination of rifampicin with PREZISTA with concomitant low dose ritonavir is contraindicated (see section 4.5).
Kombinacija rifampicina in zdravila PREZISTA skupaj z nizkim odmerkom ritonavirja je kontraindicirana (glejte poglavje 4. 5).
The combination product lopinavir/ ritonavir should not be used with PREZISTA because co-administration causes large decreases in darunavir concentrations, which may in turn significantly decrease the darunavir therapeutic effect (see section 4.5).
Kombinacije zdravil lopinavir/ ritonavir se se sme uporabljati skupaj z zdravilom PREZISTA, ker sočasna uporaba povzroči bistveno zmanjšanje koncentracij darunavirja, kar lahko povzroči bistveno zmanjšanje terapevtskega učinka (glejte poglavje 4. 5).
Herbal preparations containing St John’ s wort (Hypericum perforatum) must not be used while taking PREZISTA due to the risk of decreased plasma concentrations and reduced clinical effects of darunavir (see section 4.5).
Med jemanjem zdravila PREZISTA se ne sme uporabljati rastlinskih pripravkov, ki vsebujejo šentjanževko (Hypericum perforatum), ker lahko pride do zmanjšanja plazemskih koncentracij in kliničnega učinka darunavirja (glejte poglavje 4. 5).
Co-administration of PREZISTA with 100 mg ritonavir, with active substances that are highly dependent on CYP3A for clearance and for which elevated plasma concentrations are associated with serious and/ or life-threatening events is contraindicated.
Kontraindicirana je sočasna uporaba zdravila PREZISTA s 100 mg ritonavirja in učinkovin, pri katerih je očistek v veliki meri odvisen od CYP3A in pri katerih so povišane plazemske koncentracije povezane z resnimi in/ ali življenje ogrožujočimi dogodki.
These active substances include e. g. antiarrhythmics (amiodarone, bepridil, quinidine, systemic lidocaine), antihistamines (astemizole, terfenadine), ergot derivatives (e. g. dihydroergotamine, ergonovine, ergotamine, methylergonovine), gastrointestinal motility agents (cisapride), neuroleptics (pimozide, sertindole), sedatives/ hypnotics (triazolam, midazolam administered orally (for caution on parenterally administered midazolam, see section 4.5)) and HMG-CoA reductase inhibitors (simvastatin and lovastatin) (see section 4.5).
Med te učinkovine sodijo npr. antiaritmiki (amiodaron, bepridil, kinidin, sistemsko dani lidokain), antihistaminiki (astemizol, terfenadin), alkaloidi ergot (npr. dihidroergotamin, ergonovin, ergotamin in metilergonovin), učinkovine, ki vplivajo na motiliteto prebavnega trakta (cisaprid), nevroleptiki (pimozid, sertindol), sedativi/ hipnotiki (triazolam, midazolam apliciran peroralno (za opozorila pri parenteralni aplikaciji midazolama glejte poglavje 4. 5)) in inhibitorji HMG- CoA reduktaze (simvastatin in lovastatin) (glejte poglavje 4. 5).
Patients should be advised that current antiretroviral therapy does not cure HIV and has not been proven to prevent the transmission of HIV to others through blood or sexual contact.
Bolnike opozorite, da sedanja protiretrovirusna terapija ne pozdravi okužbe s HIV in ni dokazano, da bi preprečevala prenos virusa HIV na druge s krvjo ali spolnim odnosom.
Appropriate precautions should continue to be employed.
Še naprej morajo uporabljati ustrezne previdnostne ukrepe.
PREZISTA should only be used in combination with 100 mg of ritonavir as a pharmacokinetic enhancer (see section 5.2).
Zdravilo PREZISTA smete uporabljati le v kombinaciji s 100 mg ritonavirja kot sredstva za farmakokinetično okrepitev (glejte poglavje 5. 2).
Increasing the dose of ritonavir from that recommended in section 4.2 did not significantly affect darunavir concentrations and is not recommended.
Povečanje odmerka ritonavirja, nad vrednost priporočeno v poglavju 4. 2, ni pomembno vplivalo na koncentracijo darunavirja in zato ni priporočljivo.
As limited information is available on the use of PREZISTA in patients aged 65 and over, caution should be exercised in the administration of PREZISTA in elderly patients, reflecting the greater frequency of decreased hepatic function and of concomitant disease or other therapy (see sections 4.2 and 5.2).
Ker so podatki o uporabi zdravila PREZISTA pri bolnikih starih 65 let ali več omejeni, je potrebna previdnost pri uporabi zdravila PREZISTA pri starostnikih, ker je pri njih pogostejše slabše delovanje jeter, druge sočasne bolezni ali druge terapije (glejte poglavji 4. 2 in 5. 2).
Darunavir binds predominantly to α 1-acid glycoprotein.
Darunavir se veže predvsem na plazemski alfa- 1 kisli glikoprotein.
Therefore, protein displacement of medicinal products highly bound to α 1-acid glycoprotein cannot be ruled out.
Zato ne moremo izključiti zamenjave z drugimi zdravili, ki se z veliko afiniteto vežejo na alfa- 1 kisli glikoprotein.
Severe skin rash, which may be accompanied with fever and/ or elevations of transaminases, has occurred in 0.5% of patients treated with PREZISTA.
Pri 0, 5% bolnikov, ki so se zdravili z zdravilom PREZISTA, se je pojavil resen kožni izpuščaj, ki ga je lahko spremljala povišana telesna temperatura in/ ali povišane vrednosti transaminaz.
Erythema multiforme and Stevens-Johnson
Redko (< 0, 1%)
3 Syndrome have been rarely (< 0.1%) observed.
3 so poročali o multiformnem eritemu in Stevens- Johnsonovem sindromu.
Treatment with PREZISTA should be discontinued if such a condition develops.
Če se razvije resen kožni izpuščaj, je treba zdravljenje z zdravilom PREZISTA prekiniti.
Patients with coexisting conditions Hepatic impairment The safety and efficacy of PREZISTA have not been established in patients with severe underlying liver disorders and PREZISTA is therefore contraindicated in patients with severe hepatic impairment.
Bolniki z drugimi boleznimi ali motnjami Jetrna okvara Pri bolnikih s sočasno hudo jetrno okvaro niso dokazali varnosti in učinkovitosti zdravila PREZISTA, zato je zdravilo PREZISTA kontraindicirano pri bolnikih s hudo jetrno okvaro.
Due to an increase in the unbound darunavir plasma concentrations, PREZISTA should be used with caution in patients with mild or moderate hepatic impairment (see sections 4.2, 4.3 and 5.2).
Zaradi povišanja plazemske koncentracije nevezanega darunavirja, je treba pri bolnikih z blago do zmerno okvaro jeter zdravilo PREZISTA uporabljati previdno (glejte poglavja 4. 2, 4. 3 in 5. 2).
Patients with chronic hepatitis B or C and treated with combination antiretroviral therapy are at an increased risk for severe and potentially fatal hepatic adverse events.
Pri bolnikih s kroničnim hepatitisom B ali C, ki se zdravijo s kombinirano protiretrovirusno terapijo, obstaja povečano tveganje za pojav resnih in potencialno usodnih jetrnih neželenih učinkov.
In case of concomitant antiviral therapy for hepatitis B or C, please refer to the relevant product information for these medicinal products.
Prosimo, da v primeru kombinirane protiretrovirusne terapije za hepatitis B ali C, preberete tudi navodila za uporabo teh sočasno uporabljenih zdravil.
Patients with pre-existing liver dysfunction including chronic hepatitis have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.
Pri bolnikih z obstoječimi motnjami delovanja jeter, vključno s kroničnim hepatitisom so, med kombinirano protiretrovirusno terapijo, motnje delovanja jeter lahko pogostejše in jih je treba spremljati v skladu s standardno prakso.
If there is evidence of worsening liver disease in such patients, interruption or discontinuation of treatment should be considered.
Če opazite znake poslabševanja jetrne bolezni pri teh bolnikih, zdravljenje po potrebi prekinite ali ukinite.
Renal impairment No special precautions or dose adjustments are required in patients with renal impairment.
Ledvična okvara Pri bolnikih z ledvično okvaro posebna opozorila ali prilagoditve odmerka niso potrebna.
Therefore, no special precautions or dose adjustments are required in these patients (see sections 4.2 and 5.2).
Zato pri teh bolnikih posebna opozorila ali prilagoditve odmerka niso potrebna (glejte poglavji 4. 2 in 5. 2).
Haemophiliac patients There have been reports of increased bleeding, including spontaneous skin haematomas and haemarthrosis in patients with haemophilia type A and B treated with PIs.
Bolniki s hemofilijo Pri bolnikih s hemofilijo tipa A in B, zdravljenih z zaviralci proteaz, so poročali o povečanih krvavitvah, vključno s spontanimi kožnimi hematomi in hemartrozo.
In more than half of the reported cases, treatment with PIs was continued or reintroduced if treatment had been discontinued.
Pri več kot polovici prijavljenih primerov so z zdravljenjem z zaviralci proteaz nadaljevali ali so le- tega ponovno uvedli, če je bilo ukinjeno.
Haemophiliac patients should therefore be made aware of the possibility of increased bleeding.
Bolniki s hemofilijo se morajo zavedati možnosti povečanih krvavitev.
Diabetes mellitus/ Hyperglycaemia New onset diabetes mellitus, hyperglycaemia, or exacerbation of existing diabetes mellitus has been reported in patients receiving antiretroviral therapy, including PIs.
Sladkorna bolezen/ hiperglikemija Pri bolnikih na protiretrovirusni terapiji, vključno z zaviralci proteaz, so poročali o primerih novonastale sladkorne bolezni, hiperglikemije ali poslabšanju obstoječe sladkorne bolezni.
In some of these patients the hyperglycaemia was severe and in some cases also associated with ketoacidosis.
Pri nekaterih od teh bolnikov je bila hiperglikemija huda in v nekaterih primerih tudi povezana s ketoacidozo.
Many patients had confounding medical conditions some of which required therapy with agents that have been associated with the development of diabetes mellitus or hyperglycaemia.
Mnogi bolniki so imeli še druge bolezni in nekatere od njih so zahtevale zdravljenje z zdravili, ki jih povezujejo z nastankom sladkorne bolezni ali hiperglikemije.
Fat redistribution and metabolic disorders Combination antiretroviral therapy has been associated with redistribution of body fat (lipodystrophy) in HIV infected patients.
Prerazporeditev maščevja in presnovne motnje Pri bolnikih, okuženih s HIV, je bila kombinirana protiretrovirusna terapija povezana s prerazporeditvijo telesnega maščevja (lipodistrofijo).
Knowledge about the mechanism is incomplete.
Dolgoročne posledice tega neželenega učinka trenutno še niso znane in poznavanje tega mehanizma ni popolno.
A connection between visceral lipomatosis and PIs and lipoatrophy and NRTIs has been hypothesised.
Obstaja hipoteza o povezavi med visceralno lipomatozo in zaviralci proteaz ter lipoatrofijo in NRTI.
A higher risk of lipodystrophy has been associated with individual factors such as older age and with drug related factors such as longer duration of antiretroviral treatment and associated metabolic disturbances.
Z večjim tveganjem za lipodistrofijo so povezovali posamezne dejavnike, kot so večja starost in dejavnike, povezane z zdravilom, na primer daljše trajanje protiretrovirusnega zdravljenja in s tem povezane presnovne motnje.
Clinical examination should include evaluation for physical signs of fat redistribution.
Pri kliničnem pregledu je treba ovrednotiti tudi telesne znake prerazporeditve telesnega maščevja.
Consideration should be given to measurement of fasting serum lipids and blood glucose.
Po potrebi izmerite serumske lipide in glukozo na tešče.
Lipid disorders should be managed as clinically appropriate (see section 4.8).
Zdravljenje teh motenj je odvisno od kliničnega stanja bolnika (glejte poglavje 4. 8).
Osteonecrosis Although the etiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been
Osteonekroza Kljub temu, da so ocenili, da je vzrokov več (vključno z uporabo kortikosteroidov, uživanjem alkohola, hudo imunosupresijo, visokim indeksom telesne mase), so poročali o primerih osteonekroze,
4 reported particularly in patients with advanced HIV disease and/ or long-term exposure to combination antiretroviral therapy (CART).
4 še posebej pri bolnikih z napredovalo boleznijo HIV in/ ali dolgotrajno izpostavljenostjo kombinirani protiretrovirusni terapiji (CART - Combination Antiretroviral Therapy).
Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.
Bolnikom je treba svetovati, naj poiščejo zdravniški nasvet če se pojavijo bolečine v sklepih, okorelost sklepov ali težave pri gibanju.
Immune reactivation syndrome In HIV infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms.
Sindrom imunske reaktivacije Pri bolnikih, okuženih s HIV, ki imajo hudo imunsko pomanjkanje v času uvedbe kombinirane protiretrovirusne terapije (CART - Combination Antiretroviral Therapy), se lahko pojavi vnetna reakcija na asimptomatske ali rezidualne oportunistične povzročitelje bolezni in povzroči resna klinična stanja ali poslabšanje simptomov.
Relevant examples are cytomegalovirus retinitis, generalised and/ or focal mycobacterial infections and pneumonia caused by Pneumocystis jiroveci (formerly known as Pneumocystis carinii).
Sem sodijo citomegalovirusni retinitis, generalizirane in/ ali fokalne mikobakterijske okužbe in pljučnica, ki jo povzroča Pneumocystis jiroveci (prej znana kot Pneumocystis carinii).
In addition, reactivation of herpes simplex and herpes zoster has been observed in clinical studies with PREZISTA co-administered with 100 mg ritonavir.
V kliničnih preskušanjih z zdravilom PREZISTA in 100 mg ritonavirja so opazili tudi reaktivacijo virusov herpes simplex in herpes zoster.
Interactions with medicinal products Several of the interaction studies have been performed at lower than recommended doses of darunavir.
Medsebojno delovanje z drugimi zdravili Posamezne študije medsebojnega delovanja z drugimi zdravili so bile opravljene, pri odmerkih darunavirja, ki so bili nižji od priporočenega.
For full information on interactions with other medicinal products see section 4.5.
Za podrobnejše podatke o medsebojnih delovanjih z drugimi zdravili glejte poglavje 4. 5.
Darunavir and ritonavir are both inhibitors of the CYP3A4 isoform.
Tako darunavir kot ritonavir sta zaviralca izooblike CYP3A4.
Co-administration of darunavir and ritonavir and medicinal products primarily metabolised by CYP3A4 may result in increased systemic exposure to such medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Sočasna uporaba darunavirja in ritonavirja ter zdravil, ki se presnavljajo predvsem s CYP3A4, lahko povzroči povečano sistemsko izpostavljenost takšnim zdravilom, kar bi lahko povečalo ali podaljšalo njihov terapevtski učinek in neželene učinke.
PREZISTA co-administered with 100 mg ritonavir must not be combined with medicinal products that are highly dependent on CYP3A4 for clearance and for which increased systemic exposure is associated with serious and/ or life-threatening events (narrow therapeutic index).
Zdravila PREZISTA s 100 mg ritonavirja ne smete sočasno uporabljati z zdravili, katerih očistek je močno odvisen od CYP3A4 in pri katerih je povečana sistemska izpostavljenost povezana z resnimi in/ ali smrtno nevarnimi neželenimi učinki (majhna terapevtska širina).
These medicinal products include amiodarone, bepridil, quinidine, systemic lidocaine, astemizole, terfenadine, midazolam administered orally, triazolam, cisapride, pimozide, sertindole, simvastatin, lovastatin and the ergot alkaloids (e. g. ergotamine, dihydroergotamine, ergonovine and methylergonovine) (see section 4.3).
Med ta zdravila sodijo amiodaron, bepridil, kinidin, sistemsko dani lidokain, astemizol, terfenadin, midazolam apliciran peroralno, triazolam, cisaprid, pimozid, sertindol, simvastatin, lovastatin in alkaloidi ergot (npr. ergotamin, dihidroergotamin, ergonovin in metilergonovin) (glejte poglavje 4. 3).
The overall pharmacokinetic enhancement effect by ritonavir was an approximate 14-fold increase in the systemic exposure of darunavir when a single dose of 600 mg darunavir was given orally in combination with ritonavir at 100 mg b. i. d.
Skupni učinek farmakokinetične okrepitve z ritonavirjem je privedel do približno 14- kratnega povečanja sistemske izpostavljenosti darunavirju pri peroralni uporabi enkratnega odmerka 600 mg darunavirja v kombinaciji z ritonavirjem v odmerku 100 mg dvakrat na dan.
Therefore, PREZISTA must only be used in combination with 100 mg of ritonavir as a pharmacokinetic enhancer (see sections 4.4 and 5.2).
Zdravilo PREZISTA smete torej uporabljati samo v kombinaciji s 100 mg ritonavirja kot sredstva za farmakokinetično okrepitev (glejte poglavji 4. 4 in 5. 2).
A clinical study utilising a cocktail of drugs that are metabolised by cytochromes CYP2C9, CYP2C19 and CYP2D6 demonstrated an increase in CYP2C9 and CYP2C19 activity and inhibition of CYP2D6 activity in the presence of PREZISTA/ rtv, which may be attributed to the presence of low dose ritonavir.
Klinična študija v kateri so uporabljali mešanico zdravilnih učinkovin, ki se presnavljajo s citokromi CYP2C9, CYP2C19 in CYP2D6 je v prisotnosti zdravila PREZISTA/ rtv pokazala zvečanje aktivnosti CYP2C9 in CYP2C19 ter zmanjšanje aktivnosti CYP2D6, kar lahko pripišemo prisotnosti majhnega odmerka ritonavirja.
Co-administration of darunavir and ritonavir and medicinal products which are primarily metabolised by CYP2D6 (such as flecainide, propafenone, metoprolol) may result in increased plasma concentrations of these medicinal products, which could increase or prolong their therapeutic effect and adverse reactions.
Sočasna uporaba darunavirja, ritonavirja in zdravil, ki se presnavljajo predvsem s CYP2D6 (flekainid, propafenon, metoprolol), lahko povzroči zvečanje plazemskih koncentracij teh zdravil, kar lahko zveča ali podaljša njihov terapevtski učinek in neželene učinke.
5 Medicinal products that affect darunavir/ ritonavir exposure Darunavir and ritonavir are metabolised by CYP3A.
5 Zdravila, ki vplivajo na izpostavljenost darunavirju/ ritonavirju Darunavir in ritonavir se presnavljata z encimom CYP3A.
Medicinal products that induce CYP3A activity would be expected to increase the clearance of darunavir and ritonavir, resulting in lowered plasma concentrations of darunavir and ritonavir (e. g. rifampicin, St John’ s wort, lopinavir).
Pričakovano je, da zdravila, ki inducirajo aktivnost encima CYP3A, povečajo očistek darunavirja in ritonavirja in posledično znižajo plazemske koncentracije darunavirja in ritonavirja (npr. rifampicin, šentjanževka, lopinavir).
Co-administration of darunavir and ritonavir and other medicinal products that inhibit CYP3A may decrease the clearance of darunavir and ritonavir and may result in increased plasma concentrations of darunavir and ritonavir (e. g. indinavir, systemic azoles like ketoconazole and clotrimazole).
Sočasna uporaba darunavirja in ritonavirja z zdravili, ki inhibirajo encim CYP3A, lahko zmanjša očistek darunavirja in ritonavirja in posledično zveča plazemske koncentracije darunavirja in ritonavirja (npr. indinavir, sistemsko dani azoli, kot sta ketokonazol in klotrimazol).
These interactions are described in the interaction tables below.
Te interakcije so opisane v spodnjih preglednicah.
Interaction table Interactions between darunavir/ ritonavir and protease inhibitors, antiretroviral agents other than protease inhibitors and other non-antiretroviral medicinal products are listed in the tables below (increase is indicated as “↑”, decrease as “↓”, no change as “↔”, not determined as “ ND”, twice daily as “ b. i. d.”, once daily as “ q. d.” and once every other day as “ q. o. d.”).
Preglednica medsebojnih delovanj z drugimi zdravili Interakcije med darunavirjem/ ritonavirjem in zaviralci proteaz, drugimi protiretrovirusnimi učinkovinami in ne- protiretrovirusnimi zdravili so navedene v spodnjih preglednicah (povečanje je prikazano z “ ↑ ”, zmanjšanje z “ ↓ ”, brez spremembe “ ↔ ”, ni podatka z “ ND ”, jemanje dvakrat na dan kot “ b. i. d. ”, enkrat na dan kot “ q. d. ” in jemanje vsak drugi dan kot “ q. o. d. ”).
Several of the interaction studies (indicated by # in the table below) have been performed at lower than recommended doses of darunavir or with a different dosing regimen (see section 4.2 Posology).
Posamezne študije medsebojnega delovanja z drugimi zdravili (označene z # v spodnji preglednici) so bile opravljene pri odmerkih darunavirja, ki so bili nižji od priporočenega ali z drugačnimi režimi odmerjanja (glejte poglavje 4. 2 Odmerjanje in način uporabe).
Interactions – Darunavir/ ritonavir with Protease Inhibitors The efficacy and safety of the use of PREZISTA with 100 mg ritonavir and any other PI (e. g.
Medsebojna delovanja- darunavir/ ritonavir z zaviralci proteaz (ZP) Učinkovitost in varnost uporabe zdravila PREZISTA s 100 mg ritonavirja in katerimkoli drugim ZP (npr.
(fos)amprenavir, nelfinavir and tipranavir) has not been established in HIV patients.
(fos) amprenavir, nelfinavir in tipranavir) ni bila dokazana pri bolnikih s HIV.
Generally, dual therapy with protease inhibitors is not recommended.
Na splošno, dvojna terapija z zaviralci proteaz ni priporočljiva.
Co-administered
Sočasno
Dose of Dose of
Odmerek Odmerek
Medicinal
Preskušano
Medicinal Product
uporabljeno
Co-administered
sočasno
Product
zdravilo
Medicinal Product (mg)
uporabljenega zdravila (mg)
1,200/ 100 b. i. d.
1. 200/ 100 b. i. d.
1,200 b.i.d.
1. 200 b. i. d.